查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
缺血性中风市场报告：2030 年趋势、预测与竞争分析
市场调查报告书
商品编码
1356896

缺血性中风市场报告：2030 年趋势、预测与竞争分析

Ischemic Stroke Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

缺血性脑中风的趋势与预测

预计到 2030 年，全球缺血性中风市场将达到 71.8 亿美元，2024 年至 2030 年年复合成长率为 7.5%。这个市场的主要驱动因素是人们健康意识的提高、全球糖尿病发病率的上升以及烟草使用者数量的增加。由于CT、MRI、颈动脉超音波和脑血管摄影市场的商机，全球缺血性中风市场前景看好。

按节段分類的缺血性中风

包含按诊断、药物类别和地区分類的全球缺血性中风的估计。

缺血性中风相关企业名单

市场上的公司根据其提供的产品品质进行竞争。该市场的主要企业专注于扩大製造设施、投资研发、开拓基础设施以及利用整个价值链的整合机会。这些策略使缺血性中风公司能够满足不断增长的需求，确保竞争力，开发创新产品和技术，降低製造成本，并扩大基本客群。本报告介绍的缺血性脑中风企业如下。

  • 雅培实验室
  • 拜耳
  • 勃林格殷格翰
  • 波士顿科学公司
  • 康迪斯公司
  • 科维迪安
  • 通用电气医疗集团
  • 基因泰克公司
  • 强生公司
  • 飞利浦公司
  • 美敦力

赛诺菲缺血性中风

  • Lucintel预测，在预测期内，抗血小板药物将继续成为最大的细分市场，因为它们被用作缺血性中风的一线药物，以防止血栓形成并最大限度地降低后续中风的风险。
  • CT 可能仍然是最大的部分，因为它的周转时间短并且能够详细查看大脑解剖结构。
  • 由于该地区政府的积极配合措施和持续的技术进步，北美在预测期内仍然是最大的市场。

本报告回答了 11 个关键问题：

  • Q.1. 细分市场中最有前途和高成长的机会是什么？
  • Q.2.哪个细分市场将以更快的速度成长？为什么？
  • Q.3.您认为哪些地区未来会出现更快的成长？为什么？
  • Q.4. 影响市场动态的主要因素有哪些？市场的主要挑战和商业风险是什么？
  • Q.5. 这个市场的商业风险和竞争威胁是什么？
  • Q.6.这个市场有哪些新趋势？为什么？
  • Q.7.市场客户需求有何改变？
  • Q.8. 该市场有哪些新发展以及哪些公司处于领先地位？
  • Q.9.这个市场的主要企业有哪些？主要企业采取哪些策略配合措施来发展业务？
  • Q.10. 该市场上的竞争产品有哪些？由于材料或产品替代而导致市场占有率下降的威胁有多大？
  • Q.11.过去年度发生了哪些併购事件，对产业产生了哪些影响？

目录

第1章执行摘要

第2章全球缺血性中风市场：市场动态

  • 简介、背景、分类
  • 供应链
  • 产业驱动因素与挑战

第3章2018-2030年市场趋势及预测分析

  • 宏观经济趋势（2018-2023）与预测（2024-2030）
  • 全球缺血性中风市场趋势（2018-2023）与预测（2024-2030）
  • 按诊断分類的全球缺血性中风市场
    • CT
    • MRI
    • 颈超音波检查
    • 脑血管血管造影术
  • 按药物类别分類的全球缺血性中风市场
    • 组织纤溶酶原激活剂
    • 抗凝血物
    • 抗血小板药物
    • 抗高血压

第4章2018-2030年分地区市场趋势及预测分析

  • 全球缺血性中风市场（按地区）
  • 北美缺血性中风市场
  • 欧洲缺血性中风市场
  • 亚太地区缺血性中风市场
  • 其他区域性缺血性中风市场

第5章竞争分析

  • 产品系列分析
  • 营运整合
  • 波特五力分析

第6章成长机会与策略分析

  • 成长机会分析
    • 全球缺血性中风市场诊断成长机会
    • 按药物类别分類的全球缺血性中风市场成长机会
    • 按地区分類的全球缺血性中风市场成长机会
  • 全球缺血性中风市场的新兴趋势
  • 战略分析
    • 新产品开发
    • 全球缺血性中风市场容量扩张
    • 全球缺血性中风市场的合併、收购与合资企业
    • 认证和许可

第7章主要企业概况

  • Abott Laboratories
  • Bayer
  • Boehringer Ingelheim
  • Boston Scientific Corporation
  • Cordis Corporation
  • Covidien
  • GE Healthcare
  • Genentech
  • Johnson & Johnson
  • Koninklijke Philips NV
简介目录

Ischemic Stroke Trends and Forecast

The future of the global ischemic stroke market looks promising with opportunities in the CT, MRI, carotid ultrasounds, and cerebral angiography markets. The global ischemic stroke market is expected to reach an estimated $7.18 billion by 2030 with a CAGR of 7.5% from 2024 to 2030. The major drivers for this market are increased health awareness among people, rising diabetes rates across the globe, and growing number of tobacco users.

A more than 150-page report is developed to help in your business decisions.

Ischemic Stroke by Segment

The study includes a forecast for the global ischemic stroke by diagnosis, drug class, and region.

Ischemic Stroke Market by Diagnosis [Shipment Analysis by Value from 2018 to 2030]:

  • CT
  • MRI
  • Carotid Ultrasounds
  • Cerebral Angiography

Ischemic Stroke Market by Drug Class [Shipment Analysis by Value from 2018 to 2030]:

  • Tissue Plasminogen Activator
  • Anticoagulant
  • Antiplatelet
  • Antihypertensive

Ischemic Stroke Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Ischemic Stroke Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies ischemic stroke companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the ischemic stroke companies profiled in this report include-

  • Abbott Laboratories
  • Bayer
  • Boehringer Ingelheim
  • Boston Scientific Corporation
  • Cordis Corporation
  • Covidien
  • GE Healthcare
  • Genentech
  • Johnson & Johnson
  • Koninklijke Philips N.V.
  • Medtronic

Ischemic Stroke Sanofi

  • Lucintel forecasts that antiplatelet will remain the largest segment over the forecast period as it is used as a first-line treatment for ischemic stroke since they help prevent blood clot formation and minimize the risk of subsequent strokes.
  • CT will remain the largest segment because it ensures short turnaround time and ability to see the brain anatomy in detail.
  • North America will remain the largest segment over the forecast period due to favorable government initiatives and on-going technological advancements in the region.

Features of the Global Ischemic Stroke Market

  • Market Size Estimates: Ischemic stroke market size estimation in terms of value ($B).
  • Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
  • Segmentation Analysis: Ischemic stroke market size by diagnosis, drug class, and region. in terms of value ($B).
  • Regional Analysis: Ischemic stroke market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
  • Growth Opportunities: Analysis of growth opportunities in different diagnosis, drug class, and region.s for the ischemic stroke market.
  • Strategic Analysis: This includes M&A, new product development, and competitive landscape of the ischemic stroke market.
  • Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1. What is the ischemic stroke market size?

Answer: The global ischemic stroke market is expected to reach an estimated $7.18 billion by 2030.

Q.2. What is the growth forecast for ischemic stroke market?

Answer: The global ischemic stroke market is expected to grow with a CAGR of 7.5% from 2024 to 2030.

Q.3. What are the major drivers influencing the growth of the ischemic stroke market?

Answer: The major drivers for this market are increased health awareness among people, rising diabetes rates across the globe, and growing number of tobacco users.

Q.4. What are the major segments for ischemic stroke market?

Answer: The future of the ischemic stroke market looks promising with opportunities in the CT, MRI, carotid ultrasounds, and cerebral angiography markets.

Q.5. Who are the key Ischemic Stroke Market companies?

Answer: Some of the key ischemic stroke companies are as follows:

  • Abbott Laboratories
  • Bayer
  • Boehringer Ingelheim
  • Boston Scientific Corporation
  • Cordis Corporation
  • Covidien
  • GE Healthcare
  • Genentech
  • Johnson & Johnson
  • Koninklijke Philips N.V.

Q.6. Which ischemic stroke market segment will be the largest in future?

Answer: Lucintel forecasts that antiplatelet will remain the largest segment over the forecast period as it is used as a first-line treatment for ischemic stroke since they help prevent blood clot formation and minimize the risk of subsequent strokes.

Q.7. In ischemic stroke market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest segment over the forecast period due to favorable government initiatives and on-going technological advancements in the region.

Q.8. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the ischemic stroke market by diagnosis (CT, MRI, carotid ultrasounds, and cerebral angiography), drug class (tissue plasminogen activator, anticoagulant, antiplatelet, and antihypertensive), and region. (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Ischemic Stroke Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Ischemic Stroke Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Ischemic Stroke Market by Diagnosis
    • 3.3.1: CT
    • 3.3.2: MRI
    • 3.3.3: Carotid Ultrasounds
    • 3.3.4: Cerebral Angiography
  • 3.4: Global Ischemic Stroke Market by Drug Class
    • 3.4.1: Tissue Plasminogen Activator
    • 3.4.2: Anticoagulant
    • 3.4.3: Antiplatelet
    • 3.4.4: Antihypertensive

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Ischemic Stroke Market by Region
  • 4.2: North American Ischemic Stroke Market
    • 4.2.2: North American Ischemic Stroke Market by Drug Class: Tissue Plasminogen Activator, Anticoagulant, Antiplatelet, and Antihypertensive
  • 4.3: European Ischemic Stroke Market
    • 4.3.1: European Ischemic Stroke Market by Diagnosis: CT, MRI, Carotid Ultrasounds, and Cerebral Angiography
    • 4.3.2: European Ischemic Stroke Market by Drug Class: Tissue Plasminogen Activator, Anticoagulant, Antiplatelet, and Antihypertensive
  • 4.4: APAC Ischemic Stroke Market
    • 4.4.1: APAC Ischemic Stroke Market by Diagnosis: CT, MRI, Carotid Ultrasounds, and Cerebral Angiography
    • 4.4.2: APAC Ischemic Stroke Market by Drug Class: Tissue Plasminogen Activator, Anticoagulant, Antiplatelet, and Antihypertensive
  • 4.5: ROW Ischemic Stroke Market
    • 4.5.1: ROW Ischemic Stroke Market by Diagnosis: CT, MRI, Carotid Ultrasounds, and Cerebral Angiography
    • 4.5.2: ROW Ischemic Stroke Market by Drug Class: Tissue Plasminogen Activator, Anticoagulant, Antiplatelet, and Antihypertensive

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Ischemic Stroke Market by Diagnosis
    • 6.1.2: Growth Opportunities for the Global Ischemic Stroke Market by Drug Class
    • 6.1.3: Growth Opportunities for the Global Ischemic Stroke Market by Region
  • 6.2: Emerging Trends in the Global Ischemic Stroke Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Ischemic Stroke Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Ischemic Stroke Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Abott Laboratories
  • 7.2: Bayer
  • 7.3: Boehringer Ingelheim
  • 7.4: Boston Scientific Corporation
  • 7.5: Cordis Corporation
  • 7.6: Covidien
  • 7.7: GE Healthcare
  • 7.8: Genentech
  • 7.9: Johnson & Johnson
  • 7.10: Koninklijke Philips N.V.